<progress id="bg1ea"><track id="bg1ea"></track></progress>


      2019-nCOV IgM Antibody Assay Reagent Kit (CMIA)

      Short Description:

      The 2019-nCOV-IgM Assay Reagent Kit (CMIA) is a chemiluminescent microparticle immunoassay

      (CMIA) for the qualitative determination of COVID-19/2019-nCOV IgM antibody in human serum as an aid in the diagnosis of 2019-nCOV infections.

      Product Detail


      Product Tags

      Principles of the Procedure

      The 2019-nCOV IgM Antibody Assay Reagent Kit (CMIA) is a two-step immunoassay using magnetic particle chemiluminescence technology. It can precisely determine the presence of anti-2019-nCOVIgM antibodies in human serum or plasma.

      During the reaction, the first step is protein binding by mixing the sample with strong paramagnetic particles coated with the 2019-nCoV nuclear protein antigen. After washing, the alkaline phosphataselabeled murine anti-human IgM monoclonal antibody is added in the second step to form a magnetic particle-nucleoprotein_anti-2019-nCoV-IgM murine-anti-IgM-ALP-enzyme reaction mixture. After another wash cycle, the substrate of the alkaline phosphatase is added to the reaction mixture. The resulting chemiluminescence reaction is then measured in relative light units (RLU). The concentration of the anti-2019-nCoV -IgM antibody in the sample is proportional to the amount of relative light units (RLU) of the mixture. So the result can be used to detect the existence of the IgM in the sample and aid to determine if the patient has been infected by the 2019-nCoV virus.

      Test Type


      Incubation Time

      Time to first result





      RL C2000

      10 minutes

      39 minutes

      37 °C

      50 μL?

    1. Previous:
    2. Next:

    3. Write your message here and send it to us

      Product categories